Analystreport

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Barclays PLC from $110.00 to $125.00. They now have an "overweight" rating on the stock.

Ligand Pharmaceuticals Incorporated  (LGND) 
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.ligand.com